Francesca Palandri

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann et al. · Blood · 2007 · 745 citations · Full text

Medicine, Oncology, Pharmacology +9

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Francesco Passamonti, Toni Giorgino, Barbara Mora et al. · Leukemia · 2017 · 334 citations · Full text

Medicine, Hematology, Molecular Medicine +5

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

Francesco Passamonti, Martin Grießhammer, Francesca Palandri et al. · The Lancet Oncology · 2016 · 254 citations

Medicine, Hematology, Pharmacology +3

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

Gianantonio Rosti, Francesca Palandri, Fausto Castagnetti et al. · Blood · 2009 · 211 citations · Full text

Medicine, Oncology, Pharmacology +7

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti et al. · Blood · 2009 · 196 citations

Medicine, Oncology, Pharmacotherapy +10